TIL Therapy and Newer Options for Advanced Melanoma

Introduction

For most people with advanced melanoma, treatment begins with checkpoint inhibitor immunotherapy and, for BRAF-mutant tumors, targeted therapy. Those work well for many, but not everyone, and some melanomas that respond eventually start growing again.

When that happens, the options have expanded considerably in recent years. This page covers the newer treatments: TIL cell therapy (the first cell therapy approved for a solid tumor), oncolytic virus therapy injected into tumors, tebentafusp for a specific form of eye melanoma, and a look at what is still in trials, such as individualized cancer vaccines.

Most of these are given at specialized melanoma centers. Getting to one — and asking about clinical trials — is often the practical first step. See also how to find a melanoma specialist.

TIL Cell Therapy (Lifileucel)

Tumor-infiltrating lymphocytes, or TILs, are immune cells that have already found their way into a melanoma but are usually too few and too worn down to control it. TIL therapy takes those cells out, multiplies them enormously in a laboratory, and gives them back. Lifileucel (brand name Amtagvi) became the first TIL therapy approved for melanoma, and the first cell therapy of any kind approved for a solid tumor, for disease that has progressed after a PD-1 inhibitor (and, if BRAF-mutant, a BRAF inhibitor).

The process takes several weeks and unfolds in steps:

• •Harvest. A surgeon removes a piece of melanoma — usually a lesion at least 1.5 cm across — which is sent to a central manufacturing facility.
• •Expansion. Over about three to four weeks, the lab grows the TILs from that tumor into the billions.
• •Lymphodepletion. Just before the cells are returned, the patient receives about a week of chemotherapy to clear out existing immune cells and make room for the new ones. This is done in the hospital.
• •Infusion and interleukin-2. The expanded TILs are given back in a single infusion, followed by up to six doses of high-dose interleukin-2 (IL-2) to help the cells survive and multiply in the body.

In the pooled C-144-01 trial, in patients whose melanoma had already progressed on checkpoint inhibitors, roughly one in three responded to a single lifileucel infusion, and a meaningful share of those responses were still going a year or more later. Because it is a one-time treatment, people who respond may have long stretches with no further therapy.

The trade-off is intensity. The lymphodepleting chemotherapy and IL-2 cause a difficult week or two — low blood counts, infection risk, fevers, fluid retention, low blood pressure — that requires close inpatient monitoring at a center certified to deliver the treatment. Side effects from the chemotherapy and IL-2 generally resolve within a few weeks; the TIL cells themselves are the patient's own and are not rejected.

Tebentafusp for Uveal (Eye) Melanoma

Uveal melanoma starts in the eye and behaves very differently from melanoma of the skin. It rarely carries a BRAF mutation and responds poorly to standard checkpoint inhibitors. Tebentafusp is a different kind of drug — a bispecific protein that grabs a melanoma target with one end and a T cell with the other, physically bringing them together.

• •It is approved only for metastatic uveal melanoma in people who carry a specific tissue type, HLA-A*02:01 — a blood test done before treatment.
• •In its phase 3 trial it was the first therapy to lengthen survival in metastatic uveal melanoma, a disease with few options.
• •It is given as a weekly infusion; the first few doses can cause a "cytokine release" reaction (fever, low blood pressure, rash) and are given with close monitoring, sometimes overnight.

Tebentafusp does not have a role in melanoma of the skin. It is mentioned here because "advanced melanoma" is sometimes used loosely, and people with eye melanoma should know their treatment path is separate.

How These Fit After First-Line Treatment

When a first-line regimen stops working, the usual sequence of considerations is:

• •Switch class first if possible. Someone who progressed on anti–PD-1 alone may respond to adding ipilimumab; someone with a BRAF mutation who has not yet had targeted therapy can switch to it.
• •Consider TIL therapy for melanoma that has progressed after a PD-1 inhibitor, if there is a resectable lesion to harvest and the person is fit enough for lymphodepleting chemotherapy and IL-2.
• •Use T-VEC for the particular problem of unresectable, skin- and node-limited recurrence.
• •Look for a clinical trial at every step, not only at the end — see finding a clinical trial for advanced melanoma.

The right choice depends on the melanoma's mutation status, where it has spread, prior treatments, and overall health — decisions best made with a melanoma medical oncologist at a center that offers the full range.

Conclusion

The options after first-line treatment for advanced melanoma are broader than they have ever been. TIL therapy with lifileucel offers a one-time treatment that produces lasting responses in about a third of people whose melanoma has progressed on checkpoint inhibitors, at the cost of a demanding few weeks. T-VEC addresses unresectable skin and node disease. Tebentafusp serves a separate group — people with HLA-A*02:01–positive uveal melanoma. And individualized vaccines and new cell therapies are advancing through trials.

Nearly all of these are delivered at specialized centers. If your current treatment is no longer holding the melanoma back, ask for a referral and a clear map of what comes next.